Webinar Technology

Getting under the skin of dermatological disease using protein biomarkers

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Getting under the skin of dermatological disease using protein biomarkers

22 August 2018

12:00 p.m. ET

Register to watch recording


Dermatological diseases such as psoriasis, eczema, and alopecia are of great medical and socioeconomic significance, and are a leading cause of nonfatal disease burden for global health care. These diseases are often chronic and can have major physical and emotional impacts on sufferers, significantly reducing their quality of life. While such conditions may be classified as “skin diseases,” their underlying pathophysiology is complex, involving systemic inflammation and autoimmune processes. Exemplifying this complexity, diseases such as psoriasis are thought to be associated with increased cardiovascular risk, including myocardial infarction and stroke. Consequently, dermatological conditions represent both a challenge when it comes to penetrating their underlying biology and developing new and better therapies, and also an opportunity to gain insights into a wider range of mechanistically related diseases. Our panelists will discuss how biomarkers can contribute to these goals by improving our biological understanding and helping us to develop more effective, targeted treatments for patients in the future.

During the webinar, the speakers will:

  • Discuss the complex interplay of inflammatory and immunological processes in dermatological disease
  • Describe recent progress in understanding pathophysiology and therapeutic opportunities
  • Explore future developments and potential advances in this field
  • Answer your questions during the live broadcast!

This webinar will last for approximately 60 minutes.

Speaker bios

Emma Guttman, M.D., Ph.D.

Icahn School of Medicine at Mount Sinai
New York, NY

Dr. Guttman-Yassky is the Sol and Clara Kest Professor of Dermatology and Immunology and vice chair for research in the Department of Dermatology as well as director of the Center for Excellence in Eczema and of the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, New York. She earned her M.D. from the Sackler Faculty of Medicine at Tel-Aviv University in Israel, and a Ph.D. from Bar-Ilan University in Ramat Gan, Israel. After receiving her Israeli board certification in dermatology, she moved to the United States to pursue a postdoctoral fellowship at The Rockefeller University and a second dermatology residency at Weill Cornell Medicine, both in New York. Her major focus is atopic dermatitis (AD). She made paradigm-shifting discoveries on the immunologic basis of AD in humans, enriching the understanding of its pathophysiology and opening the door to new AD therapeutics. She has developed comprehensive molecular maps of AD, defining skin differentiation and immune circuits characterizing the disease. She has established the reversibility of the AD phenotype and defined a series of biomarkers that are now accelerating testing of novel, pathway-specific drugs for AD. Recently she has extended her research interest to alopecia areata; her findings in that area are also being translated into possible novel therapeutic targets. Dr. Guttman-Yassky cofounded and serves as president-elect of the International Eczema Council, and was elected to the American Society for Clinical Investigation and the American Dermatological Association. She received the Young Investigator Award from the American Academy of Dermatology in 2011.

James G. Krueger, M.D., Ph.D.

The Rockefeller University
New York, NY

Dr. Krueger is head of the Laboratory for Investigative Dermatology at The Rockefeller University in New York City. He also serves as a physician and codirector for the Center for Clinical and Translational Science at The Rockefeller University Hospital in New York as well as chief executive officer of the hospital. He earned his bachelor’s degree from Princeton University and a Ph.D. in virology and cell biology from The Rockefeller University. He received his M.D. from Cornell University Medical College, where he also completed an internship in internal medicine and residency in dermatology. Dr. Krueger is certified by the American Board of Dermatology. His research group at Rockefeller was the first to conduct clinical trials with specific, targeted immune antagonists in psoriasis; this work established that elimination of pathogenic T cells from skin lesions could reverse the full pathological phenotype of psoriasis. Since then, his group has used immune-based therapeutics to dissect inflammatory pathways in psoriasis and to conduct parallel pharmacogenomic studies that define mechanisms of targeted therapeutics in human populations. A more recent focus has been definition of new inflammatory pathways as well as new types of inflammatory cells in psoriasis lesions that are now being targeted with new biologic drugs.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here